Shares of Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Free Report) have earned an average recommendation of “Moderate Buy” from the five research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average […]
StockNews.com initiated coverage on shares of Amneal Pharmaceuticals (NYSE:AMRX – Free Report) in a research note published on Wednesday. The firm issued a buy rating on the stock. Other research analysts have also issued reports about the stock. Barclays boosted their price target on shares of Amneal Pharmaceuticals from $4.00 to $5.00 and gave the […]
Amneal Pharmaceuticals (NYSE:AMRX) Updates FY 2023 Earnings Guidance theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Amneal Pharmaceuticals (NYSE:AMRX – Get Free Report) issued an update on its FY 2023 earnings guidance on Friday morning. The company provided EPS guidance of $0.45-$0.55 for the period, compared to the consensus EPS estimate of $0.47. The company issued revenue guidance of $2.30 billion-$2.40 billion, compared to the consensus revenue estimate of $2.32 billion. […]
Amneal Pharmaceuticals (NYSE:AMRX – Get Free Report) had its price objective raised by stock analysts at Barclays from $4.00 to $5.00 in a research report issued on Friday, FlyOnTheWall reports. Barclays‘s price objective indicates a potential upside of 21.65% from the stock’s current price. A number of other brokerages have also weighed in on AMRX. […]